Cargando…

Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice

BACKGROUND: Monitoring osteoporosis therapy by measurement of bone turnover markers (BTMs) might detect non-compliance in an earlier stage of anti-osteoporosis treatment and improve persistence. METHODS: BTMs were measured in two groups. The first group consisted of patients newly diagnosed with ost...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eekman, Danielle A, Bultink, Irene EM, Heijboer, Annemieke C, Dijkmans, Ben AC, Lems, Willem F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146915/ https://www.ncbi.nlm.nih.gov/pubmed/21774839 http://dx.doi.org/10.1186/1471-2474-12-167

Ejemplares similares

Treatment with intravenous pamidronate is a good alternative in case of gastrointestinal side effects or contraindications for oral bisphosphonates
por: Eekman, Danielle A, et al.
Publicado: (2009)

Systemic lupus erythematosus and fractures
por: Bultink, Irene E M, et al.
Publicado: (2015)

Bisphosphonates and glucocorticoid-induced osteoporosis: cons
por: Lems, Willem F., et al.
Publicado: (2015)

Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus
por: Bultink, Irene EM, et al.
Publicado: (2006)

Inflammatory Rheumatic Disorders and Bone
por: Bultink, Irene E. M., et al.
Publicado: (2012)

Advances in Glucocorticoid-Induced Osteoporosis
por: den Uyl, Debby, et al.
Publicado: (2011)

BISPHOSPHONATE-INDUCED MAXILLOFACIAL OSTEONECROSIS IN OSTEOPOROTIC INDIVIDUALS
por: da Silva Santos, Paulo Sérgio, et al.
Publicado: (2015)

Bisphosphonate related osteonecrosis of the jaws (BRONJ) in osteoporotic males
por: Kwon, Yong-Dae, et al.
Publicado: (2016)

Prospective cohort studies on risk factors for cardiovascular events in systemic lupus erythematosus: a major challenge
por: Bultink, Irene EM
Publicado: (2010)

The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis
por: Byun, Ji-Hye, et al.
Publicado: (2017)

Gender‐Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen
por: Vlot, Mariska C, et al.
Publicado: (2019)

Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review
por: Elbers, Laura P. B., et al.
Publicado: (2021)

Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study
por: Sakai, A., et al.
Publicado: (2014)

Bisphosphonate Treatment in a Patient Affected by MPS IVA with Osteoporotic Phenotype
por: Tummolo, Albina, et al.
Publicado: (2013)

Does the Time of Postoperative Bisphosphonate Administration Affect the Bone Union in Osteoporotic Intertrochanteric Fracture of Femur?
por: Cho, Yoon Je, et al.
Publicado: (2015)

Can bone turnover markers help to define the suitability and duration of bisphosphonate drug holidays?
por: Statham, Louise, et al.
Publicado: (2020)

Age-related bone turnover markers and osteoporotic risk in native Chinese women
por: Wu, Xi-Yu, et al.
Publicado: (2014)

Association between bone turnover markers and the risk of imminent recurrent osteoporotic fracture
por: Zhang, Bo, et al.
Publicado: (2022)

Erratum to: Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study
por: Sakai, A., et al.
Publicado: (2014)

Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection
por: Vlot, Mariska C., et al.
Publicado: (2018)

Are osteoporotic fractures being adequately investigated?: A questionnaire of GP & orthopaedic surgeons
por: Chami, George, et al.
Publicado: (2006)

Eldecalcitol improves chair-rising time in postmenopausal osteoporotic women treated with bisphosphonates
por: Iwamoto, Jun, et al.
Publicado: (2014)

The effects of bisphosphonates on osteoporotic patients after lumbar fusion: a meta-analysis
por: Liu, Wen-bin, et al.
Publicado: (2018)

Baseline mineralizing surface determines the magnitude of the bisphosphonate effect on cortical bone mineralization in postmenopausal osteoporotic patients
por: Misof, B.M., et al.
Publicado: (2017)

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases
por: Addison, Christina L, et al.
Publicado: (2014)

Effects of a 'Drug Holiday' on Bone Mineral Density and Bone Turnover Marker During Bisphosphonate Therapy
por: Kong, Sung Yeol, et al.
Publicado: (2013)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

Bisphosphonates Preserve Bone Mineral Density and Suppress Bone Turnover Markers in Early Menopausal Women: A Systematic Review and Meta‐Analysis of Randomized Trials
por: Ahadzadeh Ardebili, Aria, et al.
Publicado: (2023)

Dietary Protein in Older Adults: Adequate Daily Intake but Potential for Improved Distribution
por: Cardon-Thomas, Danielle K., et al.
Publicado: (2017)

Kinetic of bone turnover markers after osteoporotic vertebral compression fractures in postmenopausal female
por: Pan, Changyu, et al.
Publicado: (2018)

Changes in Bone Turnover Markers after Osteoporotic Vertebral Compression Fractures in Males and Females
por: Jia, Zhongxiong, et al.
Publicado: (2022)

Changes in Serum Osteocalcin are Not Associated with Changes in Glucose or Insulin for Osteoporotic Patients Treated with Bisphosphonate
por: Hong, Seong-hun, et al.
Publicado: (2013)

Influence of Early Bisphosphonate Administration for Fracture Healing in Patients with Osteoporotic Proximal Humerus Fractures
por: Seo, Joong-Bae, et al.
Publicado: (2016)

Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates
por: Jeong, Ho-Gul, et al.
Publicado: (2017)

Efficacy of bisphosphonate therapy on postmenopausal osteoporotic women with and without diabetes: a prospective trial
por: Kim, Jinyoung, et al.
Publicado: (2022)

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
por: Kaneko, Tetsuya, et al.
Publicado: (2019)

Effects of palliative radiotherapy and bisphosphonate usage on bone turnover marker levels in cancer patients with osteolytic bone metastases
por: Göksel, Fatih, et al.
Publicado: (2021)

First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates
por: Tandon, Vishal R., et al.
Publicado: (2014)

Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration
por: Park, Chan Ho, et al.
Publicado: (2019)

Changes of Bone Turnover Markers and Bone Tissue Content After Severe Osteoporotic Vertebral Compression Fracture
por: Qi, Haoran, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_spg84u9i0en7kvkec67negubse